Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Target Corporation (TGT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Target CorporationTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Target Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Target Corporation trades at $158 (market cap $73.92B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Target Corporation is far larger — about 4.1× Zimmer Biomet Holdings Inc's market cap, and Target Corporation pays the higher dividend (2.85%). Which is the better fit depends on your goals.

TGTZBH
Market Cap
$73.92B$17.97B
Sector
Consumer CyclicalHealth
52-Week High
$169.90$104.26
52-Week Low
$83.68$79.58
Enterprise Value
$87.20B$25.04B
Dividend Yield
2.85%1.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Target Corporation

Target Corporation (TGT) trades at $162.71, down 1.05% on the day, with strong technical momentum and solid fundamentals. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue remains stable around $107 billion with improving profitability margins. Recent news highlights CEO Michael Fiddelke's successful turnaround strategy and the company's expanding non-merchandise revenue streams.

Target presents a balanced investment case with fair valuation metrics and strong dividend history, though competitive retail pressures and valuation expansion pose risks. Analyst consensus leans slightly bullish with a $166.67 price target, representing modest upside potential from current levels. The company's operational efficiency improvements and digital growth initiatives support continued earnings momentum.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.

The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Target Corporation

With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.

Read more on TGT

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH